There are 2789 resources available
Introduction by the chair
Presenter: Eleni Efstathiou
Session: Enhanced androgen signalling inhibition should be the treatment of choice for treatment of mCSPC rather than docetaxel
Resources:
Slides
Webcast
Yes
Presenter: Karim Fizazi
Session: Enhanced androgen signalling inhibition should be the treatment of choice for treatment of mCSPC rather than docetaxel
Resources:
Slides
Webcast
No
Presenter: Ronald De Wit
Session: Enhanced androgen signalling inhibition should be the treatment of choice for treatment of mCSPC rather than docetaxel
Resources:
Slides
Webcast
Polling 2 (led by chair)
Presenter: Eleni Efstathiou
Session: Enhanced androgen signalling inhibition should be the treatment of choice for treatment of mCSPC rather than docetaxel
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Lyudmila Bazhenova
Session: Proffered Paper session - NSCLC, metastatic 2
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Thomas Gruenberger
Session: Proffered Paper session - Gastrointestinal tumours, colorectal 2
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Ophira Ginsburg
Session: Proffered Paper session - Public policy
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Maurice Pérol
Session: Proffered Paper session - NSCLC, metastatic 2
Resources:
Slides
Webcast
Invited Discussant LBA21 and 384O
Presenter: Thomas Gruenberger
Session: Proffered Paper session - Gastrointestinal tumours, colorectal 2
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Lisa Licitra
Session: Proffered Paper session - Head and neck cancer, excl. thyroid
Resources:
Slides
Webcast